195 related articles for article (PubMed ID: 24129706)
1. Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines.
Pesch B; Taeger D; Johnen G; Gawrych K; Bonberg N; Schwentner C; Wellhäusser H; Kluckert M; Leng G; Nasterlack M; Lotan Y; Stenzl A; Brüning T;
Int Arch Occup Environ Health; 2014; 87(7):715-24. PubMed ID: 24129706
[TBL] [Abstract][Full Text] [Related]
2. Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study.
Huber S; Schwentner C; Taeger D; Pesch B; Nasterlack M; Leng G; Mayer T; Gawrych K; Bonberg N; Pelster M; Johnen G; Bontrup H; Wellhäusser H; Bierfreund HG; Wiens C; Bayer C; Eberle F; Scheuermann B; Kluckert M; Feil G; Brüning T; Stenzl A;
BJU Int; 2012 Sep; 110(5):699-708. PubMed ID: 22313585
[TBL] [Abstract][Full Text] [Related]
3. The role of haematuria in bladder cancer screening among men with former occupational exposure to aromatic amines.
Pesch B; Nasterlack M; Eberle F; Bonberg N; Taeger D; Leng G; Feil G; Johnen G; Ickstadt K; Kluckert M; Wellhäusser H; Stenzl A; Brüning T;
BJU Int; 2011 Aug; 108(4):546-52. PubMed ID: 21223477
[TBL] [Abstract][Full Text] [Related]
4. [Bladder cancer screening with urine-based tumour markers - occupational medical experience].
Nasterlack M; Feil G; Leng G; Pesch B; Huber S; Sievert KD; Johnen G; Taeger D; Mayer T; Kluckert M; Brüning T; Stenzl A
Aktuelle Urol; 2011 Mar; 42(2):128-34. PubMed ID: 21437837
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the sensitivity and specificity of urine cytology, urinary nuclear matrix protein-22 and multitarget fluorescence in situ hybridization assay in the detection of bladder cancer.
Kehinde EO; Al-Mulla F; Kapila K; Anim JT
Scand J Urol Nephrol; 2011 Mar; 45(2):113-21. PubMed ID: 21091091
[TBL] [Abstract][Full Text] [Related]
6. Chromosomal instability and bladder cancer: the UroVysion(TM) test in the UroScreen study.
Bonberg N; Taeger D; Gawrych K; Johnen G; Banek S; Schwentner C; Sievert KD; Wellhäußer H; Kluckert M; Leng G; Nasterlack M; Stenzl A; Behrens T; Brüning T; Pesch B;
BJU Int; 2013 Aug; 112(4):E372-82. PubMed ID: 23350736
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of urine NMP22 point-of-care test for the screening of bladder cancer].
Ihm CH; Kim JM; Sohn YH
Korean J Lab Med; 2007 Apr; 27(2):106-10. PubMed ID: 18094560
[TBL] [Abstract][Full Text] [Related]
8. Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study.
Pichler R; Tulchiner G; Fritz J; Schaefer G; Horninger W; Heidegger I
Int J Med Sci; 2017; 14(9):811-819. PubMed ID: 28824318
[No Abstract] [Full Text] [Related]
9. Screening and monitoring for bladder cancer: refining the use of NMP22.
Ponsky LE; Sharma S; Pandrangi L; Kedia S; Nelson D; Agarwal A; Zippe CD
J Urol; 2001 Jul; 166(1):75-8. PubMed ID: 11435827
[TBL] [Abstract][Full Text] [Related]
10. A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results.
Poulakis V; Witzsch U; De Vries R; Altmannsberger HM; Manyak MJ; Becht E
BJU Int; 2001 Nov; 88(7):692-701. PubMed ID: 11890239
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the NMP22 test and comparison with voided urine cytology in the detection of bladder cancer.
Lee KH
Yonsei Med J; 2001 Feb; 42(1):14-8. PubMed ID: 11293494
[TBL] [Abstract][Full Text] [Related]
12. Role of NMP22 Bladder Check Test in early detection of bladder cancer with recurrence.
Kundal VK; Pandith AA; Hamid A; Shah A; Kundal R; Wani SM
Asian Pac J Cancer Prev; 2010; 11(5):1279-82. PubMed ID: 21198277
[TBL] [Abstract][Full Text] [Related]
13. Prospective evaluation of fluorescence-guided cystoscopy to detect bladder cancer in a high-risk population: results from the UroScreen-Study.
Horstmann M; Banek S; Gakis G; Todenhöfer T; Aufderklamm S; Hennenlotter J; Stenzl A; Schwentner C;
Springerplus; 2014; 3():24. PubMed ID: 24478941
[TBL] [Abstract][Full Text] [Related]
14. Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma.
Lotan Y; OʼSullivan P; Raman JD; Shariat SF; Kavalieris L; Frampton C; Guilford P; Luxmanan C; Suttie J; Crist H; Scherr D; Asroff S; Goldfischer E; Thill J; Darling D
Urol Oncol; 2017 Aug; 35(8):531.e15-531.e22. PubMed ID: 28366272
[TBL] [Abstract][Full Text] [Related]
15. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat.
Sharma S; Zippe CD; Pandrangi L; Nelson D; Agarwal A
J Urol; 1999 Jul; 162(1):53-7. PubMed ID: 10379739
[TBL] [Abstract][Full Text] [Related]
16. Performance of nuclear matrix protein 22 urine marker and voided urine cytology in the detection of urinary bladder tumors.
Smrkolj T; Mihelič M; Sedlar A; Sterle I; Osredkar J; Sedmak B
Clin Chem Lab Med; 2011 Feb; 49(2):311-6. PubMed ID: 21118051
[TBL] [Abstract][Full Text] [Related]
17. NMP22 in transitional cell carcinoma of the urinary bladder.
Su CK; Yang CR; Horng YY; Kao YL; Ho HC; Ou YC; Cheng CL
J Chin Med Assoc; 2003 May; 66(5):294-8. PubMed ID: 12908572
[TBL] [Abstract][Full Text] [Related]
18. Comparative sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer.
Sánchez-Carbayo M; Herrero E; Megías J; Mira A; Soria F
J Urol; 1999 Dec; 162(6):1951-6. PubMed ID: 10569545
[TBL] [Abstract][Full Text] [Related]
19. [Cytokeratins (UBC and CYFRA 21-1) and nuclear matrix proteins (NMP22) as urine tumor markers in the diagnosis of bladder cancer].
Sánchez-Carbayo M; Urrutia M; Hernández-Cerceño ML; González de Buitrago JM; Navajo JA
Med Clin (Barc); 2000 Mar; 114(10):361-6. PubMed ID: 10786344
[TBL] [Abstract][Full Text] [Related]
20. Could nuclear matrix protein 22 (NMP22) play a role with urine cytology in screening for bladder cancer?--experience at Kuwait University.
Kapila K; Kehinde EO; Anim JT; Mojiminiyi OA; Vinsu A; George SS; Al-Maghrebi M; Al-Mulla F
Cytopathology; 2008 Dec; 19(6):369-74. PubMed ID: 18631356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
